24-Wk β-Alanine Ingestion on Muscle Taurine and Clinical Blood Parameters in Healthy Males
Not Applicable
Completed
- Conditions
- Sports Nutritional Physiological Phenomena
- Interventions
- Dietary Supplement: Beta-alanineDietary Supplement: Placebo
- Registration Number
- NCT03655041
- Lead Sponsor
- University of Sao Paulo
- Brief Summary
Although β-alanine (BA) has been shown to be an effective ergogenic aid, little information exists on the safety of chronic supplementation despite potential concerns. The aim of this study was to investigate the effects of chronic BA supplementation on muscle taurine content, blood clinical markers and sensory side-effects during 24 weeks of BA supplementation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 25
Inclusion Criteria
- Healthy males
Exclusion Criteria
- Smokers
- Chronic disease
- Prior or current use of steroids
- Use of creatine in the last 6 months
- Use of beta-alanine in the last 6 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Beta-Alanine Beta-alanine 6.4 g/day of beta-alanine for 24 weeks Placebo Placebo 6.4 g/day of maltodextrin for 24 weeks
- Primary Outcome Measures
Name Time Method Muscle taurine content in mmol/kg Up to 24 weeks Change in the content of taurine in muscle will be determined using High-Pressure Liquid Chromatography of muscle biopsies
- Secondary Outcome Measures
Name Time Method Albumin; globulin; creatinine in mg/dL Up to 24 weeks Albumin; globulin; creatinine will be analysed from venous blood samples
Aspartate transaminase; alanine aminotransferase; alkaline phosphatase; lactate dehydrogenase and creatine kinase in U/L Up to 24 weeks Aspartate transaminase; alanine aminotransferase; alkaline phosphatase; lactate dehydrogenase and creatine kinase will be analysed from venous blood samples